

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Opthea Limited (**Opthea**)

ABN

32 006 340 567

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

1 +Class of +securities issued or to be issued

Fully paid ordinary shares (**Shares**)

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

37,914,377 Shares under the institutional placement announced by Opthea on 3 April 2017 (**Placement**).

7,430,751 Shares to eligible institutional shareholders under the institutional component of the pro-rata accelerated non-renounceable entitlement offer announced by Opthea on 3 April 2017 (**Institutional Entitlement Offer**).

3,403,084 Shares to eligible retail shareholders under the retail component of the pro-rata accelerated non-renounceable entitlement offer announced by Opthea on 3 April 2017 (**Retail Entitlement Offer**, and together with the Institutional Entitlement Offer, the **Entitlement Offer**).

3,300 Shares were also issued pursuant to the exercise of options.

3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Same as existing quoted Shares.

4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

Yes.

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

In respect of the Entitlement Offer and Placement, \$0.93 per Share.

In respect of the issue of shares following the exercise of options, \$0.27 per Share.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

As described in the ASX announcement and investor presentation lodged with ASX on 3 April 2017 – namely, to raise capital to, amongst other things, fund clinical trials of Opthea’s drug compound, OPT-302, in a phase 2B clinical trial for wet age related macular degeneration and a phase 2A clinical trial for treating diabetic macular edema patients.

3,300 Shares have been issued pursuant to the exercise of quoted options.

---

+ See chapter 19 for defined terms.

6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes</p>
6b	<p>The date the security holder resolution under rule 7.1A was passed</p>	<p>28 November 2016</p>
6c	<p>Number of +securities issued without security holder approval under rule 7.1</p>	<p>22,748,711 Shares</p>
6d	<p>Number of +securities issued with security holder approval under rule 7.1A</p>	<p>15,165,666 Shares</p>
6e	<p>Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)</p>	<p>N/A</p>
6f	<p>Number of +securities issued under an exception in rule 7.2</p>	<p>10,833,835 Shares</p>
6g	<p>If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.</p>	<p>Yes. Issue price: \$0.93. 15 day VWAP (from the date that the price at which the securities were to be issued was agreed): \$0.88</p>
6h	<p>If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements</p>	<p>N/A</p>
6i	<p>Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements</p>	<p>See Annexure 1.</p>

- 7 +Issue dates  
 Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.

Wednesday, 12 April 2017 for Shares issued under the Placement and the Institutional Entitlement Offer.

Monday, 1 May 2017 in respect of the issue of Shares following the exercise of the quoted options.

Wednesday, 3 May 2017 for Shares issued under the Retail Entitlement Offer.

- 8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
200,489,590	Fully paid ordinary shares
48,171,622	Quoted options

- 9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
1,000,000	Unquoted options issued to Bell Potter Securities Limited pursuant to a Corporate Advisory Agreement.
7,000,000	Unquoted options issued to directors of Opthea.
2,625,000	Unquoted options issued to employees of Opthea.

- 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Same as existing Shares, from the date of issue.

The ability of the Company to offer dividends (if any) is contingent on it making taxable profits. The determination of any dividend is at the absolute discretion of the directors.

+ See chapter 19 for defined terms.

## Part 2 - Pro rata issue

11	Is security holder approval required?	No.
12	Is the issue renounceable or non-renounceable?	Non-renounceable.
13	Ratio in which the <sup>+</sup> securities will be offered	1 Share for every 14 Shares held as at the record date for the Entitlement Offer.
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Fully paid ordinary shares.
15	<sup>+</sup> Record date to determine entitlements	7.00pm (AEST) on Wednesday, 5 April 2017.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No.
17	Policy for deciding entitlements in relation to fractions	Where fractions arise in the calculation of the shareholders' entitlements under the Entitlement Offer they will be rounded up to the next whole number of Shares.
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	Under the Retail Entitlement Offer, all countries other than Australia and New Zealand.  Under the Institutional Entitlement Offer, all countries other than Australia, New Zealand, the United States, Hong Kong, Singapore, Finland, Germany, Switzerland, Israel and the United Kingdom.
19	Closing date for receipt of acceptances or renunciations	Institutional Entitlement Offer closed on Tuesday, 4 April 2017.  Retail Entitlement Offer closed Monday, 24 April 2017.
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A

22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	No prospectus is being prepared.  A retail offer booklet and entitlement and acceptance form in respect of the Retail Entitlement Offer was sent to eligible retail security holders on Monday, 10 April 2017.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A

---

+ See chapter 19 for defined terms.

33    +Issue date

Refer to item 7 of this Appendix 3B.

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34    Type of +securities  
(tick one)

(a)     +Securities described in Part 1

(b)     All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35     If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36     If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37     A copy of any trust deed for the additional +securities

## Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought N/A

39 +Class of +securities for which quotation is sought N/A

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? N/A

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now N/A

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	N/A	N/A

+ See chapter 19 for defined terms.



## Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: .....  
Company secretary

3 May 2017  
Date: .....

Print name: Mike Tonroe  
.....

== == == == ==

---

+ See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	150,190,303 shares
<b>Add</b> the following: <ul style="list-style-type: none"> <li>• Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	15,500 shares (issued 18 May 2016) 30,900 shares (issued 7 October 2016) 1,400,375 shares (issued 3 February 2017) 21,000 shares (issued 29 March 2017) 80,000 shares (issued 6 April 2017) 3,300 shares (issued 1 May 2017)
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	None
<b>“A”</b>	151,741,378 shares

+ See chapter 19 for defined terms.

<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply</b> “A” by 0.15	22,761,206 shares
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	22,748,711 shares (issued on 12 April 2017)
“C”	22,748,711
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	22,761,206 shares
<p><b>Subtract</b> “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	22,748,711
<p><b>Total</b> [“A” x 0.15] – “C”</p>	<p>Up to 12,495 shares</p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b>  <i>Note: number must be same as shown in Step 1 of Part 1</i>	151,741,378 shares
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10  <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	15,174,137
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	15,165,666 shares (issued on 12 April 2017)
<b>“E”</b>	15,165,666

+ See chapter 19 for defined terms.

<b>Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A</b>	
"A" x 0.10  <i>Note: number must be same as shown in Step 2</i>	15,174,137
<b>Subtract "E"</b>  <i>Note: number must be same as shown in Step 3</i>	15,165,666
<b>Total</b> ["A" x 0.10] – "E"	Up to 8,471 shares  <i>Note: this is the remaining placement capacity under rule 7.1A</i>

---

+ See chapter 19 for defined terms.